The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer
Open accessAbstract
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. In primary analysis, enzalutamide plus androgen deprivation therapy (ADT) improved radiographic progression-free survival (rPFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC); however, overall survival data were immature. In the phase III, double-blind, global ARCHES trial (ClinicalTrials.gov identifier: NCT02677896 ), 1,150 patients with mHSPC were randomly assigned 1:1 to enzalutamide (160 mg once daily) plus ADT or placebo plus ADT, stratified by disease volume and prior docetaxel use. Here, we report the final prespecified analysis of overall survival (key secondary end point) and an update on rPFS, other secondary end points, and safety. After unblinding, 180 (31.3%) progression-free patients randomly assigned to placebo plus ADT crossed over to open-label enzalutamide plus ADT. As of May 28, 2021 (median follow-up, 44.6 months), 154 of 574 patients randomly assigned to enzalutamide plus ADT and 202 of 576 patients randomly assigned to placebo plus ADT had died. Enzalutamide plus ADT reduced risk of death by 34% versus placebo plus ADT (median not reached in either group; hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P < .001). Enzalutamide plus ADT continued to improve rPFS and other secondary end points. Adverse events were generally consistent with previous reports of long-term enzalutamide use. In conclusion, enzalutamide plus ADT significantly prolongs survival versus placebo plus ADT in patients with mHSPC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Armstrong, A. J., Szmulewitz, R. Z., Petrylak, D. P., Holzbeierlein, J., Villers, A., Azad, A., Alcaraz, A., Alekseev, B., Iguchi, T., Shore, N. D., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00799 · Cited by 1,217
Self-citationKyriakopoulos, C. E., Chen, Y.-H., Carducci, M. A., Liu, G., Jarrard, D. F., Hahn, N. M., Shevrin, D. H., Dreicer, R., Hussain, M., Eisenberger, M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.3657 · Cited by 1,104
Fizazi, K., Tran, N., Fein, L., Matsubara, N., Rodriguez-Antolin, A., Alekseev, B. Y., Özgüroğlu, M., Ye, D., Feyerabend, S., Protheroe, A., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30082-8 · Cited by 833
Self-citationChi, K. N., Chowdhury, S., Bjartell, A., Chung, B. H., Pereira de Santana Gomes, A. J., Given, R., Juárez, A., Merseburger, A. S., Özgüroğlu, M., Uemura, H., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03488 · Cited by 525
Cited by
Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology
Schaeffer, E. M., Srinivas, S., Adra, N., An, Y., Barocas, D., Bitting, R., Bryce, A., Chapin, B., Cheng, H. H., D’Amico, A. V., et al. (2023) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2023.0050 · Cited by 596
Updates to Advanced Prostate Cancer: AUA/SUO Guideline (2023)
Lowrance, W., Dreicer, R., Jarrard, D. F., Scarpato, K. R., Kim, S. K., Kirkby, E., Buckley, D. I., Griffin, J. C., & Cookson, M. S. (2023) · Journal of Urology · doi:10.1097/ju.0000000000003452 · Cited by 321
Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer
Freedland, S. J., de Almeida Luz, M., De Giorgi, U., Gleave, M., Gotto, G. T., Pieczonka, C. M., Haas, G. P., Kim, C.-S., Ramirez-Backhaus, M., Rannikko, A., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2303974 · Cited by 319
Self-citationFizazi, K., & Gillessen, S. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.02.015 · Cited by 119
Metadata
- Authors
- Armstrong, A. J., Azad, A. A., Iguchi, T., Szmulewitz, R. Z., Petrylak, D. P., Holzbeierlein, J., Villers, A., Alcaraz, A., Alekseev, B., Shore, N. D., Gomez-Veiga, F., Rosbrook, B., Zohren, F., Yamada, S., Haas, G. P., & Stenzl, A.
- Venue
- Journal of Clinical Oncology
- Published
- 2022-05-20
- Volume
- 40
- Issue
- 15
- Pages
- 1616-1622
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W4224078346
- Cited by
- 316
- References
- 4
- FWCI
- 37.49
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer. https://app.cochat.ai/papers/10.1200/jco.22.00193
- The paper
- Armstrong, A. J., Azad, A. A., Iguchi, T., Szmulewitz, R. Z., Petrylak, D. P., Holzbeierlein, J., Villers, A., Alcaraz, A., Alekseev, B., Shore, N. D., Gomez-Veiga, F., Rosbrook, B., Zohren, F., Yamada, S., Haas, G. P., & Stenzl, A. (2022). Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.22.00193
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.